Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.[3][4] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000[5] (8.5% of total city employment)[6] and included hundreds of scientists, making Amgen the largest employer in Ventura County.[7][8] As of 2022, Amgen has approximately 24,000 staff in total.[9]

Amgen Inc.
FormerlyApplied Molecular Genetics (1980–1983)
TypePublic
ISINUS0311621009
IndustryBiotechnology
FoundedApril 8, 1980 (1980-04-08)
HeadquartersThousand Oaks, California, U.S.
Key people
Robert A. Bradway
(Chairman, President & CEO)
ProductsAimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix, Xgeva
RevenueIncrease US$26.32 billion (2022)
Increase US$9.57 billion (2022)
Increase US$6.55 billion (2022)
Total assetsIncrease US$65.12 billion (2022)
Total equityDecrease US$3.66 billion (2022)
Number of employees
c. 25,200 (December 2022)
Websiteamgen.com
Footnotes / references
[1][2]

In 2019, the company's largest selling products were Enbrel (etanercept),[10] a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy.[11] Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).

History
AMGen corporate logo, 1983
Argentine president Mauricio Macri meets with heads of Amgen, in 2018.

Amgen was established in Thousand Oaks in 1980.[12][7] The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[13] followed by Kevin W. Sharer in 2000.[14] Robert A. Bradway became Amgen's president and chief executive officer in May 2012 following Sharer's retirement.[15] Amgen sponsored the Tour of California from 2011 to 2017.[16]

Timeline
  • 1980: Founded in Thousand Oaks, California, as Applied Molecular Genetics, Amgen was backed by a small group of venture capitalists. Its focus in early days was on recombinant DNA technology and recombinant human insulin.[17] William Bowes from Cetus Corporation recruits Winston Salser from UCLA to start Amgen with a scientific advisory board consisting of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.[18] In October, Amgen named George Rathmann its first president and chief executive officer.[17]
  • 1983: On June 17, Amgen went public, selling two million common shares and raising nearly $40 million.[19][20][21] That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin had a breakthrough in finding and cloning the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).[22][23]
  • 1984: In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.[24]
  • 1985: Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).[23][25][26]
  • 1988: In October, Gordon Binder was named CEO, succeeding George Rathmann.[27]
  • 1989: Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).[28][29]
  • 1991: In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[30] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[31]
  • 1993: In March, Amgen opened a new manufacturing facility in Puerto Rico, which later became the company's flagship manufacturing site.[32]
  • 1994: Amgen became the fifth company to receive the U.S. Department of Commerce's National Medal of Technology and Innovation, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.[33] Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).[34]
  • 1998: In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha).[28] A 2006 assessment by the National Institute of Clinical Excellence of the United Kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors "are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints."[35] A more recent study demonstrated that compared to traditional disease-modifying anti-rheumatic drugs, treatment with etanercept improved survival, reduced cardiovascular events and reduced the incidence of hematological cancers.[36]
  • 2000: In May, Kevin Sharer became Amgen's third CEO, following Gordon Binder's retirement.[37]
  • 2001: Aranesp received FDA approval in September.[38]
  • 2002: At the beginning of the year, the FDA approved Neulasta.[39] In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).[40]
  • 2004: Sensipar (cinacalcet) was approved by the FDA.[41][42] Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.[43][44]
  • 2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal cancer.[45] Vectibix was approved by the FDA in September 2006.[46]
  • 2008: In August, Nplate (romiplostim) was approved by the FDA.[47][48]
  • 2010: On June 6, 2010, Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[49] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[50] In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[51] The clinical trials primarily enrolled patients with breast or prostate cancer.
  • 2011: Amgen acquired a manufacturing facility near Dublin, Ireland, in March.[52] In May, Amgen acquired BioVex,[53] developer of Imlygic (talimogene laherparepvec).[54] In December, Amgen and Watson Pharmaceuticals announced a collaboration to develop and commercialize several biosimilar medicines worldwide.[55]
  • 2012: Illegal marketing practices. The Los Angeles Times reported on December 18, 2012, that Amgen pleaded guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.[56] Larry Husten, a contributor at Forbes.com elaborates on AMGEN's illegal marketing practices in this case, namely that the "government accused Amgen of marketing Aranesp for indications not approved by the FDA and other illegal marketing practices".[57] One of the drugs mentioned in the lawsuit had sales of $492 million in the third quarter of 2012, down 17% from the same quarter the previous year due to "reimbursement problems and label changes".[58]
  • 2013: Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[59] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[60][61] Amgen acquired Micromet, a company focused on BiTE technology, in March.[62] In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO.[63] In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas.[64] In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv (etelcalcetide).[65][66] Amgen acquired Iceland-based deCODE Genetics in December.[67] Amgen also opened an affiliate in China.[68][69]
  • 2013: In October, Amgen acquired Onyx Pharmaceuticals, developer of Kyprolis (carfilzomib).[70]
  • 2014: In November the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[71] Later in the same week, the company in conjunction with AstraZeneca reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[72]
  • 2014: In November, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.[73] Blincyto (blinatumomab) was approved by the FDA in December.[74][75]
  • 2015: In March, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[76]
  • 2015: Repatha (evolocumab) was approved by the FDA in August.[77] In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.[78] The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[79][80] In October, the FDA approved Imlygic.[81]
  • 2016: In September, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[82] Also in September, the FDA approved Amjevita (adalimumab-atto).[83]
  • 2017: Cash returned to shareholders totalled a record $6.5 billion through dividends and share repurchases.[84] The FDA approved Parsabiv in February[85] and Mvasi (bevacizumab-awwb) in September.[86] In October, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.[87][88]
  • 2018: Amgen was ranked 123 on the Fortune 500 list of the largest United States corporations by revenue.[89] In May, Aimovig (erenumab-aooe) was approved by the FDA.[90] Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July.[91]
  • 2019: In January, Evenity (romosozumab) received approval in Japan,[92][93] followed by FDA approval in April.[94] In June, Kanjinti (trastuzumab-anns) was approved by the FDA.[95] Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities.[96] In August the company announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and Bristol-Myers Squibbs merger deal.[97][98] In October, Amgen announced it would be acquiring a 20.5% stake in the Beijing-based BeiGene for $2.7 billion.[99] In November, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment.[100] In December, the FDA approved Avsola (infliximab-axxq).[101]
  • 2020: In January, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform.[102][103] Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.[104] In April, Amgen established Amgen K.K. as the company's wholly-owned affiliate in Japan.[105][106] Amgen announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel.[107] Also in July, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.[108][109] Amgen joined the Dow Jones Industrial Average on August 24, 2020.[110] In September, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies.[111] On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years.[112] Later that month, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.[113]
  • 2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion[114][115] and Rodeo Therapeutics for up to $720 million.[116] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.[117] In June, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.[118] In July, Amgen acquired Teneobio for $900 million. In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.[119][120] Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November.[121] In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma.[122] The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.[123]
  • 2022: In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.[124][125] The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.[126][127] The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.[128][129] Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.[130][131] The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.[132][133] In August, the company agreed to acquire ChemoCentryx for $3.7 billion in an all-cash deal. ChemoCentryx is the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis—which was approved last year.[134] In December, the company announced it would acquire Horizon Therapeutics for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments.[135]
  • 2023: Amgen completed the acquisition of Horizon Therapeutics in October 2023.[136]

Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
  • Amgen (Founded 1983 as Applied Molecular Genetics)
    • Synergen Inc (Acq 1994)
    • Kinetix Pharmaceuticals Inc (Acq 2000)
    • Immunex Corporation (Acq 2002)
    • Tularik Inc (Acq 2004)
    • Abgenix Inc (Acq 2006)
    • Avidia Inc (Acq 2006)
    • Alantos Pharmaceuticals (Acq 2007)
    • Ilypsa Inc (Acq 2007)
    • BioVex Group Inc (Acq 2011)
    • Micromet Inc (Acq 2012)
    • Mustafa Nevzat İlaç (Acq 2012)
    • KAI Pharmaceuticals (Acq 2012)
    • deCODE genetics (Acq 2012)
    • Onyx Pharmaceuticals (Acq 2013)
    • NextCODE genetics (Spun off 2013)
    • Dezima Pharma (Acq 2015)
    • Catherex (Acq 2015)
    • Nuevolution AB (Acq 2019)
    • Otezla (apremilast) (Acq 2019)[137]
    • Five Prime Therapeutics (Acq 2021)[138]
    • Rodeo Therapeutics Corporation (Acq 2021)[139]
    • Teneobio (Acq 2021)
    • ChemoCentryx (Acq 2022)[140]
    • Horizon Therapeutics (Acq 2023)
      • Vidara Therapeutics International (Acq 2014)
      • Hyperion Therapeutics (Acq 2015)
      • Crealta Holdings (Acq 2015)
      • Raptor Pharmaceutical (Acq 2016)
      • River Vision Development Corp. (Acq 2017)
      • Viela Bio Inc (Acq 2021)

Products

Amgen's approved drugs or therapeutic biologicals include:

Products developed and then sold off

Pipeline and clinical trials

As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I.[145]

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.[146]

In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.[147]

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy).[148] Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.[149][150]

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.[151] Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.[152] Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.[153]

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.[154]

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.[155] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[156] and Japan.[157]

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers but one where researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month.[158]

Carbon footprint

Amgen reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y)[159] and aims to reach net zero emissions by 2027.[160]

Amgen's annual Total CO2e Emissions - Location-Based Scope 1 + Scope 2 (in kilotonnes)[159]
Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
354369292279264249243

Public-private engagement

Amgen engages with the public and private sectors in a variety of settings including to promote research and development, academic funding, event sponsorship, philanthropy, and political lobbying.

Academia

Events and conferences

Health care

Media

Medical societies

Political lobbying

Professional associations

Research and development

See also

References
  1. "About Amgen Fact Sheet". amgen.com. Retrieved 9 March 2020.
  2. "US SEC: 2022 Form 10-K Amgen Inc". U.S. Securities and Exchange Commission. February 9, 2023.
  3. Amgen History official site page accessed January 2, 2016
  4. Ronald Vogel. Pharmaceutical Economics and Public Policy. CRC Press, 2007. ISBN 9781439801345. P. 208
  5. Biasotti, Tony (9 April 2022). "In Thousand Oaks, biotech execs discuss industry's 'rising tide,' lament area's lack of housing". Pacific Coast Business Times. Retrieved 19 September 2022.
  6. "Annual Comprehensive Financial Report". City of Thousand Oaks, California. 30 June 2021. p. 156. Retrieved 19 September 2022.
  7. Baker, Pam (2002). Thousand Oaks Westlake Village: A Contemporary Portrait. Community Communications, Inc., p. 37. ISBN 978-1581920611.
  8. "Biotech giant Amgen has big plans for new plant". Moorpark Acorn. 16 February 2018.
  9. Talhelm, Matt (7 March 2022). "Amgen to offer workers an average salary of $119,510 at new facility". WRAL TechWire. Retrieved 20 September 2022.
  10. Blankenship, Kyle (27 July 2020). "The top 20 drugs by global sales in 2019". Fierce Pharma. Retrieved 12 July 2022.
  11. Hagen, Tony (4 February 2021). "Amgen Profits Get a Ride on Biosimilar Growth". The Center For Biosimilars. Retrieved 12 July 2022.
  12. Bidwell, Carol A. (1989). The Conejo Valley: Old and New Frontiers. Windsor Publications. p. 128. ISBN 978-0897812993.
  13. "Amgen, Form 10-K, Annual Report, Filing Date Mar 24, 1998". secdatabase.com. Retrieved Jan 8, 2013.
  14. "Amgen, Form 10-K405, Filing Date Mar 7, 2000". secdatabase.com. Retrieved Jan 8, 2013.
  15. "Amgen, Form 8-K, Current Report, Filing Date May 24, 2012". secdatabase.com. Retrieved Jan 8, 2013.
  16. "Amgen Tour of California". amgentourofcalifornia.com. Archived from the original on 2020-02-04. Retrieved 2020-02-07.
  17. Walsh, Robin (27 October 2010). "A history of: Amgen". pharmaphorum.com. Retrieved 10 August 2022.
  18. "Amgen—A biotechnology success story | From drug development to the mass market". Archived from the original on 2014-10-24. Retrieved 2016-09-12.
  19. "Small Company Initial Public Offerings: June 1983". Inc.com. 1 September 1983. Retrieved 10 August 2022.
  20. Ward, Nicholas (21 April 2019). "Amgen: This Beaten Down Blue Chip Is Priced To Own". TheStreet. Retrieved 10 August 2022.
  21. Timmerman, Luke (13 May 2002). "Shrewd science: Biotech giant Amgen's success reflects its savvy corporate style". The Seattle Times. Retrieved 10 August 2022.
  22. Bate, James (2 June 1989). "Biotech Detective Scores Coup : Amgen scientist spent years searching for the key to producing EPO". Los Angeles Times. Retrieved 10 August 2022.
  23. Kim, Rachel (2019). Economics and management in the biopharmaceutical industry in the USA : evolution and strategic change. London: Routledge. pp. 2002–2003. ISBN 9781351012690. Retrieved 10 August 2022.
  24. "Kirin and Amgen Hormone Venture". The New York Times. Reuters. 15 June 1984. Retrieved 10 August 2022.
  25. Murphy, Barbara (20 May 1997). "Souza to Run Research at Biotech King Amgen". Los Angeles Times. Retrieved 10 August 2022.
  26. Bendall, Linda J.; Bradstock, Kenneth F. (August 2014). "G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent". Cytokine & Growth Factor Reviews. 25 (4): 355–367. doi:10.1016/j.cytogfr.2014.07.011. PMID 25131807.
  27. "Gordon M. Binder, chief executive of Amgen..." Los Angeles Times. 17 October 1995. Retrieved 10 August 2022.
  28. "Drugs@FDA: FDA Approved Drug Products".
  29. "Amgen and its erythropoietin drugs". The Washington Post. 19 July 2012. Retrieved 20 September 2022.
  30. "Drugs@FDA: FDA Approved Drug Products".
  31. Lyman GH, Kuderer NM, Djulbegovic B (April 2002). "Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis". Am. J. Med. 112 (5): 406–11. doi:10.1016/s0002-9343(02)01036-7. PMID 11904116.
  32. Spencer, Dina (26 Sep 2019). "5 Top Pharma Manufacturers in Puerto Rico". PharmaBoardroom. Retrieved 10 August 2022.
  33. Nathans, Aaron (16 September 1994). "Amgen, Phone Entrepreneur Win Medal of Technology". Los Angeles Times. Retrieved 10 August 2022.
  34. "A Biotech Wonder Grows Up". Forbes. 3 Sep 2001. Retrieved 10 August 2022.
  35. Chen YF, Jobanputra P, Barton P, et al. (November 2006). "A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness". Health Technol Assess. 10 (42): iii–iv, xi–xiii, 1–229. doi:10.3310/hta10420. PMID 17049139.
  36. Morgan CL, Emery P, Porter D, et al. (January 2014). "Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data". Rheumatology (Oxford). 53 (1): 186–94. doi:10.1093/rheumatology/ket333. PMID 24140761.
  37. Hemp, Paul (1 July 2004). "A Time for Growth: An Interview with Amgen CEO Kevin Sharer". Harvard Business Review. Retrieved 10 August 2022.
  38. Pollack, Andrew (19 September 2001). "F.D.A. Approves New Version of Amgen Drug". The New York Times. Retrieved 10 August 2022.
  39. "FDA approves Amgen's new-generation filgrastim product, Neulasta". www.thepharmaletter.com. 2 Nov 2002. Retrieved 10 August 2022.
  40. Pollack, Andrew (17 July 2002). "Amgen Reports Its Takeover Of Immunex". The New York Times. Retrieved 10 August 2022.
  41. "New FDA Approvals". Relias Media. 1 May 2004. Retrieved 10 August 2022.
  42. "Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688". U.S. Food and Drug Administration. Retrieved 10 August 2022.
  43. Gellene, Denise (30 March 2004). "Amgen to Buy Rival Tularik". Los Angeles Times. Retrieved 10 August 2022.
  44. "Amgen buys remaining 79% of Tularik for $1.3B to boost R&D pipeline". The Pharma Letter. 4 April 2004. Retrieved 10 August 2022.
  45. Pollack, Andrew (15 December 2005). "Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer Drug". The New York Times. Retrieved 10 August 2022.
  46. Giusti, Ruthann M.; Shastri, Kaushikkumar A.; Cohen, Martin H.; Keegan, Patricia; Pazdur, Richard (May 2007). "FDA drug approval summary: panitumumab (Vectibix)". The Oncologist. 12 (5): 577–583. doi:10.1634/theoncologist.12-5-577. ISSN 1083-7159. PMID 17522246. Retrieved 10 August 2022.
  47. Heavey, Susan (22 August 2008). "U.S. FDA approves Amgen's blood platelet booster". Reuters. Retrieved 10 August 2022.
  48. Jamali, Faranak; Lemery, Steven; Ayalew, Kassa; Robottom, Suzanne; Robie-Suh, Kathy; Rieves, Dwaine; Pazdur, Richard (July 2009). "Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura". Oncology (Williston Park, N.Y.). 23 (8): 704–709. ISSN 0890-9091. PMID 19711585. Retrieved 10 August 2022.
  49. "Drugs@FDA: FDA Approved Drug Products".
  50. "www.accessdata.fda.gov" (PDF).
  51. "FDA approves Xgeva to help prevent cancer-related bone injury". Food and Drug Administration.
  52. "Amgen to buy Pfizer plant". The Irish Times. 11 March 2011. Retrieved 10 August 2022.
  53. Timmerman, Luke (24 January 2011). "Xconomy: Amgen to Acquire BioVex for Up To $1B, to Obtain Cancer-Killing Virus Therapy". Xconomy. Retrieved 10 August 2022.
  54. Dangi-Garimella, Surabhi (28 October 2015). "Cost Questions Will Follow the Approval of Amgen's Oncolytic Viral Treatment, Imlygic". AJMC. Retrieved 10 August 2022.
  55. Pollack, Andrew (20 December 2011). "Amgen Plans to Team Up With Watson on Generics". The New York Times. Retrieved 10 August 2022.
  56. Terhune, Chad (18 December 2012). "Amgen pleads guilty to improper marketing of anemia drug Aranesp". Los Angeles Times. Retrieved 2 February 2013.
  57. Husten, Larry. "Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp". Forbes. Retrieved 2 February 2013.
  58. "Article > Amgen's Aranesp fails in heart trial, Singapore plant planned". 17 January 2013.
  59. Lipton, Eric (19 January 2013). "Fiscal Footnote: Big Senate Gift to Drug Maker". New York Times. Retrieved 2 February 2013.
  60. "Jon Entine: New York Times Mum After Congressional Budget Office Rebukes Bungled Amgen/Medicare Investigation". Huffington Post. 26 February 2013.
  61. "CBO analysis shows keeping oral drugs out of ESRD bundle could save money | Nephrology News & Issues". Archived from the original on 2013-06-05.
  62. "Amgen to buy Micromet for $1.2 billion". Reuters. 26 January 2012. Retrieved 10 August 2022.
  63. "Amgen appoints CEO Robert Bradway to chair of board". PMLive. 17 December 2012. Retrieved 10 August 2022.
  64. Writer, GEN Staff (25 April 2012). "Amgen Ponies Up $700M for Turkey's Mustafa Nevzat". GEN - Genetic Engineering and Biotechnology News. Retrieved 10 August 2022.
  65. "Amgen to Pick Up Peptide Drug Firm KAI Pharmaceuticals for $315M". GEN - Genetic Engineering and Biotechnology News. 10 April 2012.
  66. Taylor, Phil (8 February 2017). "Amgen's chronic kidney disease drug Parsabiv cleared in US". PMLive. Retrieved 11 August 2022.
  67. "Amgen Buys deCODE Genetics for $415M". GEN - Genetic Engineering and Biotechnology News. 10 December 2012.
  68. Becker, Zoey (27 June 2022). "Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China". Fierce Pharma.
  69. Philippidis, Alex (1 November 2019). "Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration". GEN - Genetic Engineering and Biotechnology News. Retrieved 11 August 2022.
  70. Wright, Rob (27 Aug 2018). "Amgen's Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles". Life Science Leader. Retrieved 11 August 2022.
  71. "GEN - News Highlights:Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". GEN. 24 November 2014.
  72. "GEN - News Highlights:Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". GEN.
  73. Brennan, Zachary (21 November 2014). "Amgen launches $200m biomanufacturing facility in Singapore". BioPharma-Reporter. Retrieved 11 August 2022.
  74. Przepiorka, Donna; Ko, Chia-Wen; Deisseroth, Albert; Yancey, Carolyn L.; Candau-Chacon, Reyes; Chiu, Haw-Jyh; Gehrke, Brenda J.; Gomez-Broughton, Candace; Kane, Robert C.; Kirshner, Susan; Mehrotra, Nitin; Ricks, Tiffany K.; Schmiel, Deborah; Song, Pengfei; Zhao, Ping; Zhou, Qing; Farrell, Ann T.; Pazdur, Richard (15 September 2015). "FDA Approval: Blinatumomab". Clinical Cancer Research. 21 (18): 4035–4039. doi:10.1158/1078-0432.CCR-15-0612. ISSN 1557-3265. PMID 26374073. S2CID 207687724. Retrieved 11 August 2022.
  75. "FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia". The ASCO Post. 15 December 2014. Retrieved 11 August 2022.
  76. "GEN - News Highlights:Celimmune Licenses Amgen's AMG 714 for Celiac Disease". GEN.
  77. Kolata, Gina (27 August 2015). "F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class". The New York Times. Retrieved 11 August 2022.
  78. "For Up to $1.55B, Amgen Acquires Dezima Pharma". GEN. 16 September 2015.
  79. "Amgen bets up to $1.7B on Xencor's antibody technology". FierceBiotech. 16 September 2015.
  80. "Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs". GEN. 16 September 2015.
  81. Tontonoz, Matthew. "T-VEC is First FDA-Approved Oncolytic Virus Therapy". Cancer Research Institute. Retrieved 11 August 2022.
  82. "Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN". September 2016.
  83. Staton, Tracy (23 September 2016). "Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market". Fierce Pharma. Retrieved 11 August 2022.
  84. "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com. Retrieved 2018-05-14.
  85. Bell, Jacob (8 February 2017). "Amgen secures FDA approval for hormone drug". BioPharma Dive. Retrieved 11 August 2022.
  86. "FDA approves bevacizumab biosimilar Mvasi". GaBI Online. 22 September 2017. Retrieved 11 August 2022.
  87. Vuocolo, Alex (23 June 2020). "Khan Academy Founder Says $3M Grant Will Help Tackle Inequities in Virtual Education". Cheddar News. Retrieved 11 August 2022.
  88. D'Angelo, Alexa (29 October 2017). "Amgen Foundation awards Khan Academy $3 million to support development of biology". Ventura County Star. Retrieved 11 August 2022.
  89. "Fortune 500 company by revenue 2018 cial". www.fortune.com. Archived from the original on 2020-03-29. Retrieved 2019-03-18.
  90. Raedler, Lisa A. (15 April 2019). "Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults". American Health & Drug Benefits. 12. Retrieved 11 August 2022.
  91. "Amgen's New Bio-manufacturing Plant, Rhode Island, US". Pharmaceutical Technology. 10 August 2018. Retrieved 11 August 2022.
  92. "Evenity gets first ever approval, in Japan". The Pharma Letter. 9 January 2019. Retrieved 11 August 2022.
  93. Taylor, Phil (9 January 2019). "Amgen gets first OK for Evenity in Japan as FDA panel looms". Fierce Biotech. Retrieved 11 August 2022.
  94. Liu, Angus (10 April 2019). "Amgen bone drug Evenity finally wins its FDA green light, but there's a catch". Fierce Pharma. Retrieved 11 August 2022.
  95. "FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti". The Center For Biosimilars. 13 June 2019. Retrieved 11 August 2022.
  96. "Amgen to buy Copenhagen-based Nuevolution for $167 million". Reuters. 22 May 2019 – via uk.reuters.com.
  97. "Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits".
  98. "Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion". Reuters. 26 August 2019.
  99. "Amgen acquires stake in BeiGene to grow cancer drug business to China". 31 October 2019.
  100. "CDC Foundation Active Programs October 1, 2020 – September 30, 2021". CDC Foundation. 2021-12-09. Archived from the original on 2022-01-15. Retrieved 2022-08-06.
  101. "FDA approves Avsola, fourth Remicade biosimilar". www.healio.com. 6 Dec 2019. Retrieved 11 August 2022.
  102. Kelly, Rhea (24 January 2020). "Amgen and Harvard Launch Free Online Science Ed Platform -- Campus Technology". Campus Technology. Retrieved 11 August 2022.
  103. Kahn, Natalie L.; Wang, Andy Z. (8 April 2020). "Harvard's LabXChange Provides Platform for Remote Scientific Learning During Pandemic | News | The Harvard Crimson". The Harvard Crimson. Retrieved 11 August 2022.
  104. "Amgen, AT&T, Others Announce Commitments for COVID-19 Response". Philanthropy News Digest. 25 March 2020. Retrieved 20 September 2022.
  105. "BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan". Reuters. 1 April 2020. Retrieved 11 August 2022.
  106. Liu, Angus (23 January 2020). "Amgen wades deeper into Asia with full control of an Astellas Japanese JV". Fierce Pharma. Retrieved 11 August 2022.
  107. "Amgen defeats Novartis appeal over arthritis drug Enbrel's patents". Reuters. 1 July 2020. Retrieved 11 August 2022.
  108. "Amgen Foundation awards $3 million to Khan Academy". Philanthropy News Digest. 24 July 2020. Retrieved 20 September 2022.
  109. Molina, Brett (30 July 2020). "Q&A: Khan Academy CEO Sal Khan on the new school year and virtual learning". USA Today. Retrieved 20 September 2022.
  110. Stevens, Pippa (24 August 2020). "Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average". CNBC. Retrieved 11 August 2022.
  111. Blankenship, Kyle (17 September 2020). "Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails". Fierce Pharma. Retrieved 11 August 2022.
  112. Manfredi, Lucas (18 January 2021). "CEOs are driving an initiative to hire, train 1M Black workers over next 10 years". FOXBusiness. Retrieved 11 August 2022.
  113. "FDA Approves Riabni, Third Biosimilar to Rituxan". Clinical Oncology News. 18 December 2020. Retrieved 20 September 2022.
  114. "Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash".
  115. "Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market". Reuters. 4 March 2021.
  116. "In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million".
  117. ASCO Post Staff (June 25, 2021). "FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". ASCO Post. Retrieved March 4, 2022.
  118. Idrus, Amirah Al (1 June 2021). "Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal". Fierce Biotech. Retrieved 20 September 2022.
  119. Taylor, Nick Paul (7 October 2021). "Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D". Fierce Biotech. Retrieved 20 September 2022.
  120. "Amgen to invest $100 million in SoftBank-backed Neumora". Reuters. 7 October 2021. Retrieved 20 September 2022.
  121. "Amgen breaks ground on new biomanufacturing facility in Ohio, US". NS Healthcare. 8 November 2021. Retrieved 20 September 2022.
  122. Dunleavy, Kevin (20 December 2021). "Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire". Fierce Pharma. Retrieved 20 September 2022.
  123. "U.S. FDA approves expanded use of Amgen's psoriasis drug". Reuters. 20 December 2021. Retrieved 20 September 2022.
  124. Armstrong, Annalee (6 January 2022). "Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs". Fierce Biotech. Retrieved 23 September 2022.
  125. Philippidis, Alex (6 January 2022). "Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  126. Armstrong, Annalee (11 January 2022). "JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal". Fierce Biotech. Retrieved 23 September 2022.
  127. Pagliarulo, Ned (11 January 2022). "Amgen partners with Arrakis to develop drugs aimed at RNA". BioPharma Dive. Retrieved 23 September 2022.
  128. Shasteen, Hayley (3 February 2022). "Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact". BioSpace. Retrieved 23 September 2022.
  129. LaHucik, Kyle (3 February 2022). "Amgen enters hot protein degradation field with $500M biobucks deal with Plexium". Fierce Biotech. Retrieved 23 September 2022.
  130. Pequeño IV, Antonio (23 February 2022). "Amgen Issues 'Green Bond'". San Fernando Valley Business Journal. Retrieved 23 September 2022.
  131. Mutua, David Caleb (29 March 2022). "Amgen Mulls More Green Bonds After 'Robust Interest' in Debut". www.bloomberg.com. Retrieved 23 September 2022.
  132. Parker, Jason (7 March 2022). "Amgen expects new Holly Springs plant to be 'a permanent home'". WRAL TechWire. Retrieved 11 July 2023.
  133. Sterling, John (11 March 2022). "Amgen Breaks Ground on NC Biomanufacturing Facility". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  134. Walker, Joseph (4 August 2022). "Amgen to Buy ChemoCentryx for $3.7 Billion". The Wall Street Journal. Archived from the original on 4 August 2022.
  135. Mishra, Manas; Satija, Bhanvi (12 December 2022). "Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal". Reuters.
  136. "Amgen completes $27.8 billion Horizon deal". Reuters. 6 October 2023.
  137. Erman, Michael; Mishra, Manas (26 August 2019). "Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion". Reuters. Retrieved 23 September 2022.
  138. Adams, Ben (4 March 2021). "Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset". Fierce Biotech. Retrieved 23 September 2022.
  139. Idrus, Amirah Al (30 March 2021). "Amgen saddles up with Rodeo for a $55M trek into regenerative medicine". Fierce Biotech. Retrieved 23 September 2022.
  140. Philippidis, Alex (5 August 2022). "Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  141. Food and Drug Administration December 3, 2014 FDA Press release: Blinatumomab
  142. Jeffries, Fleur (28 March 2022). "Amgen shares new Otezla data at American Academy of Dermatology congress 2022". PMLive. Retrieved 11 August 2022.
  143. Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine
  144. "Stemgen® (ancestim)". sobi.com. Archived from the original on 2013-12-30. Retrieved 2013-12-30.
  145. "Amgen Pipeline". Amgen Pipeline. Retrieved 16 August 2022.
  146. Lisa Astor (September 9, 2019). "FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC". targetedonc.com. Retrieved November 16, 2019.
  147. Liu, Angus (3 August 2020). "AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study". Fierce Pharma.
  148. Helwick, Caroline (1 Feb 2021). "Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC". The ASCO Post. Retrieved 16 August 2022.
  149. "Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More". Yahoo Finance. 28 Oct 2020. Retrieved 16 August 2022.
  150. Ross, Casey (10 November 2020). "Drug companies deliver a vote of confidence in adaptive trial for Covid-19". STAT. Retrieved 16 August 2022.
  151. Beasley, Deena (30 November 2020). "COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs". Reuters. Retrieved 16 August 2022.
  152. Gardner, Jonathan (23 Nov 2020). "Amgen cuts Cytokinetics loose after heart drug disappointment". BioPharma Dive. Retrieved 16 August 2022.
  153. Dembeck, Lauren (18 October 2021). "NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma". Pulmonology Advisor. Retrieved 16 August 2022.
  154. Taylor, Nick Paul (8 December 2020). "Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib". Fierce Biotech. Retrieved 16 August 2022.
  155. ASCO Post Staff (June 25, 2021). "FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". ascopost.com. Retrieved March 4, 2022.
  156. Kristi Rosa (January 10, 2022). "Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC". www.onclive.com. Retrieved March 4, 2022.
  157. Audrey Sternberg (January 20, 2022). "Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC". cancernetwork.com. Retrieved March 4, 2022.
  158. Walker, Joseph (2022-09-12). "New Cancer Drug Beats Chemotherapy in Study". Wall Street Journal. ISSN 0099-9660. Retrieved 2022-09-12.
  159. "Amgen's ESG Datasheet for 2020Q4" (PDF). Alt URL
  160. "Amgen's Sustainability Report for 2020Q4" (PDF). Archived from the original (PDF) on July 17, 2021. Alt URL
  161. Simonyi, Charles; Dijkgraaf, Robbert (2013). "Report for the Academic Year 2012-2013" (PDF). Institute for Advanced Study. Archived (PDF) from the original on 2022-08-02. Retrieved 2022-08-02.
  162. "Amgen Biotech Experience (ABE-LA)". LA Promise Fund. 2022-02-23. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  163. "Donor Listing". University of Toronto. Archived from the original on 2021-04-23. Retrieved 2022-08-06.
  164. "Honor Roll of Donors" (PDF). University of Washington; Amazon Web Services. 2020. Archived (PDF) from the original on 2022-06-10. Retrieved 2022-08-05.
  165. BUKSA Strategic Conference Services (2021). "Virtual Series Sponsor Profile: Amgen". Alberta Kidney Days Virtual Series. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  166. "Compassion in kidney care: from patients to providers" (PDF). BC Renal Agency. 2013. Archived (PDF) from the original on 2022-01-08. Retrieved 2022-08-02.
  167. "Sponsors". Mentoring in IBD. 2022. Archived from the original on 2022-04-19. Retrieved 2022-08-02.
  168. "The 8th Princess Margaret Hospital Conference: Developments in Cancer Management". FDocuments India. 2020-07-17. Archived from the original on 2022-06-20. Retrieved 2022-08-05.
  169. "Recognizing your contribution". Kingston University Hospital Foundation. 2019-12-31. Archived from the original on 2022-08-03. Retrieved 2022-08-04.
  170. Fukakusa, Janice; Yamashita, Miyo. "2021 Annual Report" (PDF). Princess Margaret Cancer Centre. Archived (PDF) from the original on 2021-11-20. Retrieved 2022-08-05.
  171. "Donor List". Providence Health Care. Archived from the original on 2022-02-08. Retrieved 2022-08-05.
  172. "Our Donors". Scarborough Health Network Foundation. 2021. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  173. "2020-21 SickKids Annual Report". SickKids Foundation. 2021. Archived from the original on 2022-06-20. Retrieved 2022-08-05.
  174. "Donor List - Cumulative". Sinai Health Annual Report. 2021-03-31. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  175. "St. Michael's Foundation 2020/21 Annual Report". FlippingBook. 2021. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  176. "Our donors - Your Impact". Sunnybrook Foundation. 2022. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  177. Hanson, Tennys; Kothari, Raj. "2020/21 Report to Our Donors". UHN Foundation. Archived from the original on 2022-05-07. Retrieved 2022-08-06.
  178. "Donor Listings". Women's College Hospital Foundation. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  179. "The Power of Philanthropy" (PDF). National Geographic Society. Archived (PDF) from the original on 2022-05-10. Retrieved 2022-08-04.
  180. "Corporate Support". American Society of Hematology. 2022. Archived from the original on 2022-06-10. Retrieved 2022-08-02.
  181. "Partners". Arthritis Society. 2022. Archived from the original on 2022-05-14. Retrieved 2022-08-02.
  182. "2019 Donors to the CSHP Foundation by Giving Level". Canadian Society of Hospital Pharmacists. Archived from the original on 2022-04-19. Retrieved 2022-08-04.
  183. "Our Partners". CSN/SCN. 2022. Archived from the original on 2022-01-08. Retrieved 2022-08-02.
  184. "Corporate Liaison Board". Endocrine Society. 2022. Archived from the original on 2022-06-10. Retrieved 2022-08-02.
  185. "Why sponsor the EURObservational Registry Programme". European Society of Cardiology. 2022. Archived from the original on 2022-06-15. Retrieved 2022-08-03.
  186. "AGM 2010: The Many Faces of Medical Women" (PDF). Federation of Medical Women in Canada. 2010. Archived (PDF) from the original on 2022-03-06. Retrieved 2022-08-03.
  187. "List of Members". Alliance for a Stronger FDA. 2022-03-04. Archived from the original on 2022-07-08. Retrieved 2022-08-02.
  188. "How We're Funded Advocacy & Support". Alliance for Aging Research. 2022. Archived from the original on 2022-07-15. Retrieved 2022-08-02.
  189. "Member Listings". BIOTECanada. 2021-12-23. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  190. Grumet, Jason (2016). "Dialogue Issue III: The Annual Report Issue 2015-2016" (PDF). Bipartisan Policy Center. Archived (PDF) from the original on 2022-07-07. Retrieved 2022-08-02.
  191. "Active Members". The Business Council. 2022. Archived from the original on 2022-07-13. Retrieved 2022-07-02.
  192. "CDC Foundation Active Programs". CDC Foundation. 2021-12-09. Archived from the original on 2022-01-15. Retrieved 2022-08-02.
  193. "Industry Network". CCRM. 2019-04-10. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  194. "Corporate Members". Council on Foreign Relations. Retrieved 2022-08-02.
  195. "Membership". European Federation of Pharmaceutical Industries and Associations. 2022. Archived from the original on 2022-07-01. Retrieved 2022-08-02.
  196. "2020 Donors". FNIH 2020 Annual Report. Archived from the original on 2022-03-16. Retrieved 2022-08-03.
  197. "Explore Our Collaborations". Global Health Progress. 2022. Archived from the original on 2022-04-03. Retrieved 2022-08-04.
  198. "Members". Health Products Stewardship Association. 2022. Archived from the original on 2022-04-27. Retrieved 2022-08-04.
  199. "Member Companies". Innovative Medicines Canada. 2021. Archived from the original on 2022-05-31. Retrieved 2022-08-04.
  200. "Companies". IFPMA. Archived from the original on 2022-07-01. Retrieved 2022-08-04.
  201. "Our Sponsors". Life Sciences British Columbia. 2021-01-06. Archived from the original on 2022-04-25. Retrieved 2022-08-04.
  202. Higgins, Connie (2020-04-28). "Amgen Foundation commits $2M to Ventura and Los Angeles Counties COVID-19 response" (PDF). Amgen. Archived (PDF) from the original on 2022-07-06. Retrieved 2022-08-04.
  203. "Our Members". National Health Council. 2022. Archived from the original on 2022-04-06. Retrieved 2022-08-05.
  204. "Current Members". Personalized Medicine Coalition. 2021. Archived from the original on 2021-08-15. Retrieved 2022-08-05.
  205. Pharmaceutique, Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité. "PAAB : About". www.paab.ca. Retrieved 2022-08-05.
  206. "About". Pharmaceutical Research and Manufacturers of America. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  207. Winckler, Susan C.; Woodcock, Janet (2021-07-01). "Annual Report 2020" (PDF). Reagan-Udall Foundation. Archived (PDF) from the original on 2022-07-12. Retrieved 2022-08-05.
  208. "Member Organizations". Research!America. 2022. Archived from the original on 2022-04-06. Retrieved 2022-08-05.
  209. "Our Sponsors and Prizes". BC Pharmacy Association. 2022. Archived from the original on 2022-05-23. Retrieved 2022-08-02.
  210. "Current Sponsors". Canadian Association of Gastroenterology. 2022. Archived from the original on 2022-04-21. Retrieved 2022-08-02.
  211. "Corporate Partners". CAR - Canadian Association of Radiologists. 2022. Archived from the original on 2022-07-19. Retrieved 2022-08-02.
  212. "Corporate Sponsors - CRA". Canadian Rheumatology Association. 2017-11-18. Archived from the original on 2022-03-01. Retrieved 2022-08-02.
  213. "Home". CUA Meeting 2022. 2021. Archived from the original on 2022-05-16. Retrieved 2022-08-02.
  214. "Our Partnerships". Colorectal Cancer Canada. 2021. Archived from the original on 2022-05-16. Retrieved 2022-08-02.
  215. "Your impact". Ontario Medical Association. 2022. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  216. Hemmelgarn, Brenda R.; Clement, Fiona; Manns, Braden J.; Klarenbach, Scott; James, Matthew T.; Ravani, Pietro; Pannu, Neesh; Ahmed, Sofia B.; MacRae, Jennifer; Scott-Douglas, Nairne; Jindal, Kailash (2009-10-19). "Overview of the Alberta Kidney Disease Network". BMC Nephrology. 10 (1): 30. doi:10.1186/1471-2369-10-30. ISSN 1471-2369. PMC 2770500. PMID 19840369.
  217. "Funding Partners". Can-SOLVE CKD Network. 2022. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  218. Wartell, Sarah Rosen. "2020 Annual Report" (PDF). Urban Institute. Archived (PDF) from the original on 2022-06-30. Retrieved 2022-08-05.
Wikimedia Commons has media related to Amgen.
  • Official website
  • Business data for Amgen:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.